miR-497 Target Gene Regulatory Network in Angiosarcoma
Authors:
- Annaleigh BentonABAnnaleigh Benton
- Noah M. MoriartyNMNoah M. Moriarty
- Emma TerwilligerETEmma Terwilliger
- Bozhi LiuBLBozhi Liu
- Ant MurphyAMAnt Murphy
- Hannah MaluvacHMHannah Maluvac
- Mae ShuMSMae Shu
- Lauren E. GartenhausLGLauren E. Gartenhaus
- Nimod D. JansonNJNimod D. Janson
- Claire M. PfefferCPClaire M. Pfeffer
- Sagar M. UtturkarSUSagar M. Utturkar
- Elizabeth I. ParkinsonEPElizabeth I. Parkinson
- 21 May 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 22 (9) , 879-890
Abstract
Angiosarcoma is a vascular sarcoma that is highly aggressive and metastatic. Because of its rarity, treatment options for patients are limited. Therefore, more research is needed to identify possible therapeutic vulnerabilities. We previously found that conditional deletion of Dicer1 drives angiosarcoma development in mice. Given the role of DICER1 in canonical miRNA biogenesis, this suggests that miRNA loss is important in angiosarcoma development. After testing miRNAs previously suggested to have a tumor-suppressive role in angiosarcoma, miRNA-497-5p (miR-497) suppressed cell viability most significantly. We also found that miR-497 overexpression led to significantly reduced cell migration and tumor formation. To understand the mechanism of miR-497 in tumor suppression, we identified clinically relevant target genes using a combination of RNA-sequencing data in an angiosarcoma cell line, expression data from patients with angiosarcoma, and target prediction algorithms. We validated miR-497 direct regulation of cyclin-D2, cyclin-dependent kinase 6, and vesicle amine transport protein 1 (VAT1). One of these genes, VAT1, is an understudied protein that has been suggested to promote cell migration and metastasis in other cancers. Indeed, we find that pharmacologic inhibition of VAT1 with the natural product neocarzilin A reduces angiosarcoma migration. Implications: This work supports the potent tumor-suppressive abilities of miR-497 in angiosarcoma, providing evidence for its potential as a therapeutic agent, and provides insight into the mechanisms of tumor suppression through analysis of the target gene regulatory network of miR-497.Keywords
All Related Versions
Funding Information
- National Cancer Institute (P30CA023168)
- Department of Biological Sciences, Purdue University (Ross Lynn Fellowship)
- Graduate School, Purdue University (Ross Fellowship)
- National Institutes of Health (T32 GM125620)
- Ralph W. and Grace M. Showalter Research Trust Fund
- Purdue University Center for Cancer Research
This publication has 53 references indexed in Scilit:
- Ultrafast one‐pass FASTQ data preprocessing, quality control, and deduplication using fastpiMeta, 2023
- Genetic context of oncogenic drivers dictates vascular sarcoma development in aP2‐Cre miceThe Journal of Pathology, 2022
- MicroRNA-340 inhibits the growth and invasion of angiosarcoma cells by targeting SIRT7Biomedicine & Pharmacotherapy, 2018
- Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From Non-myogenic Endothelial ProgenitorsCancer Cell, 2018
- Defining a Cancer Dependency MapCell, 2017
- Endothelial miRNAs as Cellular Messengers in Cardiometabolic DiseasesTrends in Endocrinology & Metabolism, 2017
- An Optimized microRNA Backbone for Effective Single-Copy RNAiCell Reports, 2013
- Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomasCancer, 2012
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009
- Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA TargetsCell, 2005